Details for Patent: 9,474,751
✉ Email this page to a colleague
Title: | Combination of brimonidine and timolol for topical ophthalmic use |
Abstract: | Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans. |
Inventor(s): | Chang; Chin-Ming (Tustin, CA), Beck; Gary J. (Fullerton, CA), Pratt; Cynthia C. (Mission Viejo, CA), Batoosingh; Amy L. (Mission Viejo, CA) |
Assignee: | ALLERGAN SALES, LLC (Irvine, CA) |
Filing Date: | Jun 24, 2016 |
Application Number: | 15/192,729 |
Claims: | 1. A method of treating a patient with glaucoma or ocular hypertension comprising administering twice daily to an affected eye a single composition comprising 0.2% w/v brimonidine tartrate and 0.5% w/v timolol free base, wherein the method is as effective as the administration of 0.2% w/v brimonidine tartrate monotherapy three times per day. 2. The method of claim 1, wherein the composition further comprises about 0.005% w/v benzalkonium chloride. 3. The method of claim 2, wherein the composition further comprises sodium phosphate monobasic monohydrate, sodium phosphate buffer, sodium hydroxide, hydrochloric acid, and water. 4. The method of claim 1, wherein the composition further comprises 0.005% w/v benzalkonium chloride, 0.43% w/v sodium phosphate monobasic monohydrate, 2.15% w/v sodium phosphate dibasic heptahydrate, sodium hydroxide, hydrochloric acid, and water. 5. The method of claim 4, wherein the composition has a pH of about 6.9. 6. The method of claim 5, wherein the method reduces the incidence of one or more adverse events selected from the group consisting of conjunctival hyperemia, oral dryness, eye pruritus, allergic conjunctivitis, foreign body sensation, conjunctival folliculosis, and somnolence when compared to the administration of 0.2% w/v brimonidine tartrate monotherapy three times daily. |